Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy
Summary What is known and Objective It is now estimated that about 5% of cetuximab‐treated patients and about 3% of panitumumab‐treated patients will develop grade 3–4 hypomagnesemia. The aim of this study was to assess the extent of magnesium monitoring in patients treated with epidermal growth fac...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 2013-04, Vol.38 (2), p.101-103 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 103 |
|---|---|
| container_issue | 2 |
| container_start_page | 101 |
| container_title | Journal of clinical pharmacy and therapeutics |
| container_volume | 38 |
| creator | do Pazo-Oubiña, F. Estefanell-Tejero, A. Riu-Viladoms, G. Anglada-Martínez, H. Molas-Ferrer, G. Creus-Baró, N. |
| description | Summary
What is known and Objective
It is now estimated that about 5% of cetuximab‐treated patients and about 3% of panitumumab‐treated patients will develop grade 3–4 hypomagnesemia. The aim of this study was to assess the extent of magnesium monitoring in patients treated with epidermal growth factor receptor (EGFR)‐targeting antibodies and to estimate the incidence of hypomagnesemia in these patients at our institution.
Methods
A 2‐year retrospective study was carried out. At least four doses of weekly cetuximab or two doses of bi‐weekly panitumumab were required for inclusion. Serum magnesium profiles were reviewed from 1 month before treatment until 3 months after treatment discontinuation, and patients with |
| doi_str_mv | 10.1111/jcpt.12028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1431980962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3070086681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4618-8bea9891f353983a4831ebb594dd66b00a485e1fc0f3dfc18ea010cc6a58f1823</originalsourceid><addsrcrecordid>eNp90E1v1DAQBmALgdrtx4UfgCIhLpVSPHbiOEe0QD-0paAu4mg5znjrJYlTO6uy_56kuy03fLE9ejxjvYS8BXoO4_q4Nv1wDowy-YrMgIs8ZQXQ12RGmSjTrGDFITmKcU0pFQXjB-SQcVbIjMKM1Dd61WF0mzZpfecGH1y3SvqgzeAMJq6byt40vtNNorvBpdi7GkM7XlfBPw73iR2tD0lAg_10mFTla4cxGe4x6H57Qt5Y3UQ83e_H5OfXL8v5Zbq4vbiaf1qkJhMgU1mhLmUJlue8lFxnkgNWVV5mdS1ERelYyRGsoZbX1oBETYEaI3QuLUjGj8n7Xd8--IcNxkGt_SaMP48KMg6lpKWY1NlOmeBjDGhVH1yrw1YBVVOgagpUPQU64nf7lpuqxfqFPic4gg97oKPRjQ26My7-cwXNpZTZ6GDnHl2D2_-MVNfz78vn4enujYsD_nl5o8NvJQpe5OrXtwv1eZkvbu7uSvWD_wX8sJ5G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1431980962</pqid></control><display><type>article</type><title>Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>do Pazo-Oubiña, F. ; Estefanell-Tejero, A. ; Riu-Viladoms, G. ; Anglada-Martínez, H. ; Molas-Ferrer, G. ; Creus-Baró, N.</creator><creatorcontrib>do Pazo-Oubiña, F. ; Estefanell-Tejero, A. ; Riu-Viladoms, G. ; Anglada-Martínez, H. ; Molas-Ferrer, G. ; Creus-Baró, N.</creatorcontrib><description>Summary
What is known and Objective
It is now estimated that about 5% of cetuximab‐treated patients and about 3% of panitumumab‐treated patients will develop grade 3–4 hypomagnesemia. The aim of this study was to assess the extent of magnesium monitoring in patients treated with epidermal growth factor receptor (EGFR)‐targeting antibodies and to estimate the incidence of hypomagnesemia in these patients at our institution.
Methods
A 2‐year retrospective study was carried out. At least four doses of weekly cetuximab or two doses of bi‐weekly panitumumab were required for inclusion. Serum magnesium profiles were reviewed from 1 month before treatment until 3 months after treatment discontinuation, and patients with <2 determinations were excluded.
Results and Discussion
Two hundred and one patients received at least one dose of EGFR‐targeting antibodies, but only 68 met the inclusion criteria. Seventy patients had <2 magnesium determinations. The overall hypomagnesemia was 58·82% (40 of 68 patients), with a 4·41% grade 3 hypomagnesemia (three of 68 patients). No grade 4 hypomagnesemia was detected.
What is new and Conclusion
There is a lack of magnesium monitoring in these patients. Serum magnesium determinations should be done every 4–8 weeks in patients treated with EGFR‐targeting antibodies, as it is a useful surrogate marker for both toxicity and efficacy.</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1111/jcpt.12028</identifier><identifier>PMID: 23278401</identifier><identifier>CODEN: JCPTED</identifier><language>eng</language><publisher>Oxford: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Biological and medical sciences ; Cetuximab ; Female ; Humans ; hypomagnesemia ; magnesium ; Magnesium - blood ; Male ; Medical sciences ; Metabolic diseases ; Metals (hemochromatosis...) ; Middle Aged ; Other metabolic disorders ; panitumumab ; Pharmacology. Drug treatments ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Receptor, Epidermal Growth Factor - immunology ; Retrospective Studies</subject><ispartof>Journal of clinical pharmacy and therapeutics, 2013-04, Vol.38 (2), p.101-103</ispartof><rights>2012 Blackwell Publishing Ltd</rights><rights>2014 INIST-CNRS</rights><rights>2012 Blackwell Publishing Ltd.</rights><rights>Copyright © 2013 Blackwell Publishing Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4618-8bea9891f353983a4831ebb594dd66b00a485e1fc0f3dfc18ea010cc6a58f1823</citedby><cites>FETCH-LOGICAL-c4618-8bea9891f353983a4831ebb594dd66b00a485e1fc0f3dfc18ea010cc6a58f1823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjcpt.12028$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjcpt.12028$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27058884$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23278401$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>do Pazo-Oubiña, F.</creatorcontrib><creatorcontrib>Estefanell-Tejero, A.</creatorcontrib><creatorcontrib>Riu-Viladoms, G.</creatorcontrib><creatorcontrib>Anglada-Martínez, H.</creatorcontrib><creatorcontrib>Molas-Ferrer, G.</creatorcontrib><creatorcontrib>Creus-Baró, N.</creatorcontrib><title>Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy</title><title>Journal of clinical pharmacy and therapeutics</title><addtitle>J Clin Pharm Ther</addtitle><description>Summary
What is known and Objective
It is now estimated that about 5% of cetuximab‐treated patients and about 3% of panitumumab‐treated patients will develop grade 3–4 hypomagnesemia. The aim of this study was to assess the extent of magnesium monitoring in patients treated with epidermal growth factor receptor (EGFR)‐targeting antibodies and to estimate the incidence of hypomagnesemia in these patients at our institution.
Methods
A 2‐year retrospective study was carried out. At least four doses of weekly cetuximab or two doses of bi‐weekly panitumumab were required for inclusion. Serum magnesium profiles were reviewed from 1 month before treatment until 3 months after treatment discontinuation, and patients with <2 determinations were excluded.
Results and Discussion
Two hundred and one patients received at least one dose of EGFR‐targeting antibodies, but only 68 met the inclusion criteria. Seventy patients had <2 magnesium determinations. The overall hypomagnesemia was 58·82% (40 of 68 patients), with a 4·41% grade 3 hypomagnesemia (three of 68 patients). No grade 4 hypomagnesemia was detected.
What is new and Conclusion
There is a lack of magnesium monitoring in these patients. Serum magnesium determinations should be done every 4–8 weeks in patients treated with EGFR‐targeting antibodies, as it is a useful surrogate marker for both toxicity and efficacy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Cetuximab</subject><subject>Female</subject><subject>Humans</subject><subject>hypomagnesemia</subject><subject>magnesium</subject><subject>Magnesium - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Metals (hemochromatosis...)</subject><subject>Middle Aged</subject><subject>Other metabolic disorders</subject><subject>panitumumab</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Receptor, Epidermal Growth Factor - immunology</subject><subject>Retrospective Studies</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90E1v1DAQBmALgdrtx4UfgCIhLpVSPHbiOEe0QD-0paAu4mg5znjrJYlTO6uy_56kuy03fLE9ejxjvYS8BXoO4_q4Nv1wDowy-YrMgIs8ZQXQ12RGmSjTrGDFITmKcU0pFQXjB-SQcVbIjMKM1Dd61WF0mzZpfecGH1y3SvqgzeAMJq6byt40vtNNorvBpdi7GkM7XlfBPw73iR2tD0lAg_10mFTla4cxGe4x6H57Qt5Y3UQ83e_H5OfXL8v5Zbq4vbiaf1qkJhMgU1mhLmUJlue8lFxnkgNWVV5mdS1ERelYyRGsoZbX1oBETYEaI3QuLUjGj8n7Xd8--IcNxkGt_SaMP48KMg6lpKWY1NlOmeBjDGhVH1yrw1YBVVOgagpUPQU64nf7lpuqxfqFPic4gg97oKPRjQ26My7-cwXNpZTZ6GDnHl2D2_-MVNfz78vn4enujYsD_nl5o8NvJQpe5OrXtwv1eZkvbu7uSvWD_wX8sJ5G</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>do Pazo-Oubiña, F.</creator><creator>Estefanell-Tejero, A.</creator><creator>Riu-Viladoms, G.</creator><creator>Anglada-Martínez, H.</creator><creator>Molas-Ferrer, G.</creator><creator>Creus-Baró, N.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope></search><sort><creationdate>201304</creationdate><title>Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy</title><author>do Pazo-Oubiña, F. ; Estefanell-Tejero, A. ; Riu-Viladoms, G. ; Anglada-Martínez, H. ; Molas-Ferrer, G. ; Creus-Baró, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4618-8bea9891f353983a4831ebb594dd66b00a485e1fc0f3dfc18ea010cc6a58f1823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Cetuximab</topic><topic>Female</topic><topic>Humans</topic><topic>hypomagnesemia</topic><topic>magnesium</topic><topic>Magnesium - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Metals (hemochromatosis...)</topic><topic>Middle Aged</topic><topic>Other metabolic disorders</topic><topic>panitumumab</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Receptor, Epidermal Growth Factor - immunology</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>do Pazo-Oubiña, F.</creatorcontrib><creatorcontrib>Estefanell-Tejero, A.</creatorcontrib><creatorcontrib>Riu-Viladoms, G.</creatorcontrib><creatorcontrib>Anglada-Martínez, H.</creatorcontrib><creatorcontrib>Molas-Ferrer, G.</creatorcontrib><creatorcontrib>Creus-Baró, N.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>do Pazo-Oubiña, F.</au><au>Estefanell-Tejero, A.</au><au>Riu-Viladoms, G.</au><au>Anglada-Martínez, H.</au><au>Molas-Ferrer, G.</au><au>Creus-Baró, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><addtitle>J Clin Pharm Ther</addtitle><date>2013-04</date><risdate>2013</risdate><volume>38</volume><issue>2</issue><spage>101</spage><epage>103</epage><pages>101-103</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><coden>JCPTED</coden><abstract>Summary
What is known and Objective
It is now estimated that about 5% of cetuximab‐treated patients and about 3% of panitumumab‐treated patients will develop grade 3–4 hypomagnesemia. The aim of this study was to assess the extent of magnesium monitoring in patients treated with epidermal growth factor receptor (EGFR)‐targeting antibodies and to estimate the incidence of hypomagnesemia in these patients at our institution.
Methods
A 2‐year retrospective study was carried out. At least four doses of weekly cetuximab or two doses of bi‐weekly panitumumab were required for inclusion. Serum magnesium profiles were reviewed from 1 month before treatment until 3 months after treatment discontinuation, and patients with <2 determinations were excluded.
Results and Discussion
Two hundred and one patients received at least one dose of EGFR‐targeting antibodies, but only 68 met the inclusion criteria. Seventy patients had <2 magnesium determinations. The overall hypomagnesemia was 58·82% (40 of 68 patients), with a 4·41% grade 3 hypomagnesemia (three of 68 patients). No grade 4 hypomagnesemia was detected.
What is new and Conclusion
There is a lack of magnesium monitoring in these patients. Serum magnesium determinations should be done every 4–8 weeks in patients treated with EGFR‐targeting antibodies, as it is a useful surrogate marker for both toxicity and efficacy.</abstract><cop>Oxford</cop><pub>Blackwell Publishing Ltd</pub><pmid>23278401</pmid><doi>10.1111/jcpt.12028</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-4727 |
| ispartof | Journal of clinical pharmacy and therapeutics, 2013-04, Vol.38 (2), p.101-103 |
| issn | 0269-4727 1365-2710 |
| language | eng |
| recordid | cdi_proquest_journals_1431980962 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Biological and medical sciences Cetuximab Female Humans hypomagnesemia magnesium Magnesium - blood Male Medical sciences Metabolic diseases Metals (hemochromatosis...) Middle Aged Other metabolic disorders panitumumab Pharmacology. Drug treatments Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - immunology Retrospective Studies |
| title | Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A36%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Magnesium%20monitoring%20practice%20in%20monoclonal%20anti-epidermal%20growth%20factor%20receptor%20antibodies%20therapy&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=do%20Pazo-Oubi%C3%B1a,%20F.&rft.date=2013-04&rft.volume=38&rft.issue=2&rft.spage=101&rft.epage=103&rft.pages=101-103&rft.issn=0269-4727&rft.eissn=1365-2710&rft.coden=JCPTED&rft_id=info:doi/10.1111/jcpt.12028&rft_dat=%3Cproquest_cross%3E3070086681%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1431980962&rft_id=info:pmid/23278401&rfr_iscdi=true |